Which of the following is NOT a safety concern of long‑term proton pump inhibitor therapy: increased risk of fractures, decreased risk of gastritis due to higher gastric pH, hypomagnesemia, or increased risk of pneumonia?

Decreased Risk of Gastritis Due to Higher Gastric pH is NOT a Safety Concern

The correct answer is "decreased risk of gastritis due to higher gastric pH" because this represents a potential benefit rather than a safety concern, whereas the other three options (fractures, hypomagnesemia, and pneumonia) are all established or suspected adverse effects of long-term PPI therapy. 1, 2

Why the Other Options ARE Safety Concerns

Fractures

• Meta-analysis of 24 observational studies demonstrated a 20% greater risk of hip fracture with PPI use (RR: 1.20; 95% CI: 1.14,1.28), though large randomized controlled trials including the COMPASS trial found no differences in fracture rates between PPI and placebo groups 1
• The association appears strongest in patients with pre-existing risk factors (diabetes, CKD, arthritis) and ≥2 years of use 1
• The American Geriatrics Society notes that PPIs can lower stomach acid levels, decreasing calcium absorption and increasing fracture risk 2
• Despite conflicting evidence from RCTs versus observational studies, fractures remain a recognized potential safety concern requiring monitoring 1, 2

Hypomagnesemia

• Meta-analysis shows 71% higher risk of hypomagnesemia with PPI use (adjusted OR: 1.71; 95% CI: 1.33,2.19) 1
• Both symptomatic and asymptomatic hypomagnesemia has been reported in patients treated with PPIs for at least 3 months, most commonly after 1 year of therapy 1
• Long-term PPI use is associated with established risk of hypomagnesemia, requiring appropriate monitoring 1, 2

Pneumonia

• The American Gastroenterological Association notes that long-term PPI therapy is associated with an increased risk of community-acquired pneumonia, with a dose-dependent association and 67% higher odds in long-term users (OR=1.67; 95% CI: 1.04-2.67) 1
• PPIs increase the risk of community-acquired pneumonia, but not hospital-acquired pneumonia, particularly in vulnerable populations 1
• Higher doses are more strongly associated with community-acquired pneumonia, though causality remains unproven 3

Why Decreased Risk of Gastritis is NOT a Concern

The Gastric pH Paradox

• While elevated gastric pH from PPIs might theoretically reduce acid-related gastritis, this represents a therapeutic effect rather than an adverse safety concern 1
• The American Gastroenterological Association notes that PPIs may increase susceptibility to gastroenteritis and other enteric infections due to reduced gastric acid barrier—this is the actual safety concern related to altered gastric pH 1, 2
• Japanese population-based data suggest possible association with gastric cancer (not decreased gastritis risk), though rates were similar between PPIs versus H2-receptor antagonists 1

The Real Gastric Safety Concerns

• Enterochromaffin-Like (ECL) cell hyperplasia is demonstrated in up to 50% of patients receiving PPIs for >2.5 years, though considered a benign histologic change 1
• Increased susceptibility to Clostridium difficile infection and bacterial gastroenteritis due to reduced gastric acid barrier represents the actual infection-related safety concern 1, 2

Evidence Quality Context

• The American Gastroenterological Association emphasizes that all studies reporting specific associations between PPIs and serious adverse events have been observational and cannot establish causality, while randomized controlled trials comparing PPIs with placebo have consistently shown no higher rate of adverse events among PPI users 1
• Many reported associations lack plausible mechanisms of action and are likely explained by residual confounding and analytic biases 1
• Despite these limitations, fractures, hypomagnesemia, and pneumonia remain recognized potential safety concerns in clinical practice, whereas decreased gastritis risk would represent a benefit, not a concern 1, 2, 4, 5